Repligen (RGEN) Common Equity (2010 - 2026)

Repligen (RGEN) has 17 years of Common Equity data on file, last reported at $2.1 billion in Q1 2026.

• On a quarterly basis, Common Equity rose 6.04% year-over-year to $2.1 billion in Q1 2026; TTM through Mar 2026 was $2.1 billion, a 6.04% increase from a year earlier, with the FY2025 full-year figure at $2.1 billion, up 6.76% from the prior year.
• Common Equity for Q1 2026 stood at $2.1 billion, roughly flat from $2.1 billion in the prior quarter.
• Over the last five years, Common Equity for RGEN reached as high as $2.1 billion in Q4 2025 and fell as low as $1.8 billion in Q1 2022.
• Historically, Common Equity has averaged $2.0 billion across 5 years, with a median of $2.0 billion in 2024.
• Across the five-year window, Common Equity rose 13.51% in 2022 and climbed 0.4% in 2024, its largest moves.
• Year by year, Common Equity stood at $1.9 billion in 2022, then rose by 2.83% to $2.0 billion in 2023, then advanced by 0.4% to $2.0 billion in 2024, then increased by 6.76% to $2.1 billion in 2025, then fell by 0.03% to $2.1 billion in 2026.
• Per Business Quant data, the three most recent Common Equity figures were $2.1 billion in Q1 2026, $2.1 billion in Q4 2025, and $2.1 billion in Q3 2025.